DK2914282T3 - Recombinant clostridium botulinum neurotoxins - Google Patents

Recombinant clostridium botulinum neurotoxins Download PDF

Info

Publication number
DK2914282T3
DK2914282T3 DK13811605.8T DK13811605T DK2914282T3 DK 2914282 T3 DK2914282 T3 DK 2914282T3 DK 13811605 T DK13811605 T DK 13811605T DK 2914282 T3 DK2914282 T3 DK 2914282T3
Authority
DK
Denmark
Prior art keywords
bont
protein
sequence
chain
asn
Prior art date
Application number
DK13811605.8T
Other languages
Danish (da)
English (en)
Inventor
Philip Marks
Aimee Cossins
Matthew Beard
Original Assignee
Ipsen Bioinnovation Ltd
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Ltd, Ipsen Biopharm Ltd filed Critical Ipsen Bioinnovation Ltd
Application granted granted Critical
Publication of DK2914282T3 publication Critical patent/DK2914282T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK13811605.8T 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins DK2914282T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201219602A GB201219602D0 (en) 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins
PCT/GB2013/052845 WO2014068317A1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Publications (1)

Publication Number Publication Date
DK2914282T3 true DK2914282T3 (en) 2018-02-26

Family

ID=47358958

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13811605.8T DK2914282T3 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
DK17201198.3T DK3326644T3 (da) 2012-10-31 2013-10-31 Rekombinante clostridium botulinum-neurotoksiner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17201198.3T DK3326644T3 (da) 2012-10-31 2013-10-31 Rekombinante clostridium botulinum-neurotoksiner

Country Status (26)

Country Link
US (1) US10030238B2 (cg-RX-API-DMAC7.html)
EP (3) EP3326644B1 (cg-RX-API-DMAC7.html)
JP (2) JP2019068823A (cg-RX-API-DMAC7.html)
KR (2) KR102264478B1 (cg-RX-API-DMAC7.html)
CN (2) CN110499321A (cg-RX-API-DMAC7.html)
AR (2) AR093309A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013340610B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015005384A2 (cg-RX-API-DMAC7.html)
CA (1) CA2885519A1 (cg-RX-API-DMAC7.html)
DK (2) DK2914282T3 (cg-RX-API-DMAC7.html)
EA (1) EA201590794A8 (cg-RX-API-DMAC7.html)
ES (2) ES2788199T3 (cg-RX-API-DMAC7.html)
GB (1) GB201219602D0 (cg-RX-API-DMAC7.html)
HU (2) HUE048802T2 (cg-RX-API-DMAC7.html)
IL (1) IL237623B (cg-RX-API-DMAC7.html)
IN (1) IN2015MN00436A (cg-RX-API-DMAC7.html)
MX (2) MX367080B (cg-RX-API-DMAC7.html)
NO (1) NO2914282T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ705575A (cg-RX-API-DMAC7.html)
PL (2) PL2914282T3 (cg-RX-API-DMAC7.html)
PT (2) PT3326644T (cg-RX-API-DMAC7.html)
SG (2) SG10201701140WA (cg-RX-API-DMAC7.html)
TW (3) TWI626307B (cg-RX-API-DMAC7.html)
UA (1) UA118837C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014068317A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201501449B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
RU2746736C2 (ru) * 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
KR20180114891A (ko) 2016-03-02 2018-10-19 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소를 포함하는 조성물
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
US10369190B2 (en) 2016-09-13 2019-08-06 Allergan, Inc. Non-protein clostridial toxin compositions
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
EP3694489A4 (en) 2017-10-11 2021-06-30 Illustris Pharmaceuticals, Inc. METHOD AND COMPOSITION OF TOPICAL ADMINISTRATION
US11634460B2 (en) * 2018-01-29 2023-04-25 Ipsen Biopharm Limited Non-neuronal snare-cleaving botulinum neurotoxins
EP3752128B1 (de) * 2018-02-16 2025-01-15 preclinics discovery GmbH Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202015618D0 (en) * 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin
CN115819526A (zh) * 2022-12-02 2023-03-21 海雅美生物技术(珠海)有限公司 一种重组肉毒杆菌神经毒素及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
EP1119626B1 (en) 1998-07-10 2008-01-02 U.S. Army Medical Research Institute of Infectious Diseases Botulinum neurotoxin vaccine
KR100876060B1 (ko) * 1999-08-25 2008-12-26 알러간, 인코포레이티드 활성화가능한 재조합 신경독
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
AU2005327457B2 (en) * 2003-09-25 2012-08-23 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
WO2006011966A1 (en) * 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
US20110111483A1 (en) * 2004-06-30 2011-05-12 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type E
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
JP5134540B2 (ja) * 2005-09-19 2013-01-30 アラーガン、インコーポレイテッド クロストリジウム毒素活性化クロストリジウム毒素
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
EP2038299A2 (en) * 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2009014854A1 (en) * 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins
KR20110106346A (ko) 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
JP5764550B2 (ja) * 2009-04-14 2015-08-19 エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド 遺伝子工学的ボツリヌス神経毒
AU2010353292A1 (en) * 2009-12-16 2012-07-12 Allergan, Inc. Modified Clostridial toxins comprising an integrated protease cleavage site-binding domain
WO2012112434A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
EP3504226A1 (en) * 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin

Also Published As

Publication number Publication date
SG10201701140WA (en) 2017-04-27
TW202012622A (zh) 2020-04-01
EA201590794A1 (ru) 2015-08-31
EP2914282B1 (en) 2017-12-20
GB201219602D0 (en) 2012-12-12
TWI626307B (zh) 2018-06-11
IL237623B (en) 2019-05-30
BR112015005384A2 (pt) 2017-08-08
TWI673361B (zh) 2019-10-01
UA118837C2 (uk) 2019-03-25
EP3326644B1 (en) 2020-03-04
AR117738A2 (es) 2021-08-25
PL2914282T3 (pl) 2018-07-31
AU2018203556B2 (en) 2020-08-20
US20150247139A1 (en) 2015-09-03
IL237623A0 (en) 2015-04-30
MX367080B (es) 2019-08-05
KR20200110470A (ko) 2020-09-23
MX2019009222A (es) 2019-11-21
CN104755098A (zh) 2015-07-01
PT2914282T (pt) 2018-03-13
JP2019068823A (ja) 2019-05-09
IN2015MN00436A (cg-RX-API-DMAC7.html) 2015-09-04
KR20150094590A (ko) 2015-08-19
MX2015005156A (es) 2015-09-23
SG11201502372SA (en) 2015-05-28
ZA201501449B (en) 2016-08-31
AU2020244481A1 (en) 2020-10-29
AU2018203556A1 (en) 2018-06-07
EP3673914A1 (en) 2020-07-01
US10030238B2 (en) 2018-07-24
TW201435084A (zh) 2014-09-16
EP2914282A1 (en) 2015-09-09
NZ705575A (en) 2019-08-30
CA2885519A1 (en) 2014-05-08
KR102264478B1 (ko) 2021-06-15
ES2788199T3 (es) 2020-10-20
PL3326644T3 (pl) 2020-08-24
KR102188539B1 (ko) 2020-12-09
EP3673914B1 (en) 2021-10-27
EA201590794A8 (ru) 2016-01-29
PT3326644T (pt) 2020-05-29
DK3326644T3 (da) 2020-05-11
TW201825680A (zh) 2018-07-16
AU2013340610A1 (en) 2015-03-19
JP2020078321A (ja) 2020-05-28
CN110499321A (zh) 2019-11-26
HUE048802T2 (hu) 2020-08-28
ES2662402T3 (es) 2018-04-06
HUE036764T2 (hu) 2018-07-30
AR093309A1 (es) 2015-05-27
WO2014068317A1 (en) 2014-05-08
HK1208359A1 (en) 2016-03-04
NO2914282T3 (cg-RX-API-DMAC7.html) 2018-05-19
AU2013340610B2 (en) 2018-02-22
EP3326644A1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
DK2914282T3 (en) Recombinant clostridium botulinum neurotoxins
US20230285521A1 (en) Composition comprising recombinant clostridium neurotoxin
HK40015514A (en) Recombinant clostridium botulinum neurotoxins
JP2015534814A (ja) 組換えクロストリジウムボツリヌス神経毒
HK1254485B (en) Recombinant clostridium botulinum neurotoxins
HK1254485A1 (en) Recombinant clostridium botulinum neurotoxins
HK1208359B (en) Recombinant clostridium botulinum neurotoxins